Anti-Proteinuric Response to ACEI, ARB and Diuretics Combination.
Information source: Nantes University Hospital
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Heavy Proteinuria
Intervention: ramipril 5 mg + valsartan 80 mg/day, (Drug); ramipril 10 mg + valsartan 160 mg/day, (Drug); ramipril 5 mg + valsartan 80 mg/day + increased dosage of furosémide. (Drug)
Phase: Phase 4
Status: Active, not recruiting
Sponsored by: Nantes University Hospital Official(s) and/or principal investigator(s):
Vincent LM Esnault, MD PHD, Principal Investigator, Affiliation: CHU de Nantes
Summary
Determine the best strategy for proteinuria lowering in patients with proteinuria > 1 g/day
receiving ACEI and ARB combination: either increase of ACEI and ARB dosage or increase of
diuretic dosage.
Clinical Details
Study design: Randomized, Open Label, Active Control, Crossover Assignment, Efficacy Study
Eligibility
Minimum age: 18 Years.
Maximum age: 80 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- proteinuria > 1 g/day with ramipril 5 + valsartan 80 mg/day for 2 months, proteinuria
changes < 50% on 3 separate dosages over 2 months. Exclusion criteria: age < 18 or >
80 years, systolic BP < 110 or ≥ 140 mmHg, serum creatinine > 250 mmole/L, serum
creatinine increase on ramipril + valsartan > 20%, intolerance to ACEI or ARB.
Exclusion Criteria:
-
Locations and Contacts
CHU de Nantes, Nantes, France
Additional Information
Last updated: September 13, 2005
|
